| Dr Philip Tc Chan, MD | |
|
821 S Garfield Ave, Suite 101, Alhambra, CA 91801-5839 | |
| (626) 284-7300 | |
| (626) 284-7374 |
| Full Name | Dr Philip Tc Chan |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 46 Years |
| Location | 821 S Garfield Ave, Alhambra, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174681134 | NPI | - | NPPES |
| 00G395961 | Medicaid | CA | |
| 00G395960 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | G39596 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| San Gabriel Valley Medical Center | San gabriel, CA | Hospital |
| Entity Name | Philip T C Chan Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285767798 PECOS PAC ID: 2264475888 Enrollment ID: O20050606000313 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
Researchers at the Institute of Neurosciences at Universitat Aut-noma de Barcelona (INc-UAB) identified the fundamental role played by the Nurr1 gene in neuron survival associated with synaptic activity. The discovery, published in the Journal of Biological Chemistry, allows scientists to study a new target that could help to understand the relationship between alterations in neural connections, which are known to cause early cognitive deficit, and the neurodegeneration characteristic of Alzheimer's disease.
Today the Baylor Health Care System Foundation announced gifts exceeding $20 million for what will be North Texas' largest outpatient cancer center and first dedicated hospital focusing on cancer patients.
Researchers at the University of California, San Diego School of Medicine say neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance - the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.
› Verified 8 days ago
| Entity Name | Obhg California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215258892 PECOS PAC ID: 8729276795 Enrollment ID: O20101217000826 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
Researchers at the Institute of Neurosciences at Universitat Aut-noma de Barcelona (INc-UAB) identified the fundamental role played by the Nurr1 gene in neuron survival associated with synaptic activity. The discovery, published in the Journal of Biological Chemistry, allows scientists to study a new target that could help to understand the relationship between alterations in neural connections, which are known to cause early cognitive deficit, and the neurodegeneration characteristic of Alzheimer's disease.
Today the Baylor Health Care System Foundation announced gifts exceeding $20 million for what will be North Texas' largest outpatient cancer center and first dedicated hospital focusing on cancer patients.
Researchers at the University of California, San Diego School of Medicine say neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance - the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip Tc Chan, MD 821 S Garfield Ave, Suite 101, Alhambra, CA 91801-5839 Ph: (626) 284-7300 | Dr Philip Tc Chan, MD 821 S Garfield Ave, Suite 101, Alhambra, CA 91801-5839 Ph: (626) 284-7300 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
Researchers at the Institute of Neurosciences at Universitat Aut-noma de Barcelona (INc-UAB) identified the fundamental role played by the Nurr1 gene in neuron survival associated with synaptic activity. The discovery, published in the Journal of Biological Chemistry, allows scientists to study a new target that could help to understand the relationship between alterations in neural connections, which are known to cause early cognitive deficit, and the neurodegeneration characteristic of Alzheimer's disease.
Today the Baylor Health Care System Foundation announced gifts exceeding $20 million for what will be North Texas' largest outpatient cancer center and first dedicated hospital focusing on cancer patients.
Researchers at the University of California, San Diego School of Medicine say neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance - the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.
› Verified 8 days ago
Haiping Wang, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 123 N Garfield Ave, #d, Alhambra, CA 91801 Phone: 626-570-0467 Fax: 626-570-0673 | |
Mr. John Chau Chiang, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1048 S Garfield Ave, 301, Alhambra, CA 91801 Phone: 626-282-5153 Fax: 626-282-9230 | |
Dr. Elsie Eh-she Wu, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1048 S Garfield Ave, Alhambra, CA 91801 Phone: 626-289-1009 Fax: 626-289-1033 | |
Dr. Brian Chin-jen Su, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 320 S Garfield Ave, Suite 226, Alhambra, CA 91801 Phone: 626-943-9536 Fax: 626-943-9529 | |
Che-yang Huang, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1000 S Garfield Ave, Alhambra, CA 91801 Phone: 626-281-3383 | |
Karim A. Soliman, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 84 S Palm Ave, Alhambra, CA 91801 Phone: 626-280-9968 Fax: 877-400-0565 |